Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001140361-21-028115
Filing Date
2021-08-12
Accepted
2021-08-12 16:54:10
Documents
67
Period of Report
2021-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q brhc10027659_10q.htm   iXBRL 10-Q 1313810
2 EXHIBIT 31.1 brhc10027659_ex31-1.htm EX-31.1 10415
3 EXHIBIT 31.2 brhc10027659_ex31-2.htm EX-31.2 10358
4 EXHIBIT 32.1 brhc10027659_ex32-1.htm EX-32.1 7480
5 EXHIBIT 32.2 brhc10027659_ex32-2.htm EX-32.2 7651
  Complete submission text file 0001140361-21-028115.txt   6425043

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA ocup-20210630.xsd EX-101.SCH 59663
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE ocup-20210630_cal.xml EX-101.CAL 40072
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE ocup-20210630_def.xml EX-101.DEF 289270
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE ocup-20210630_lab.xml EX-101.LAB 690369
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ocup-20210630_pre.xml EX-101.PRE 422290
11 EXTRACTED XBRL INSTANCE DOCUMENT brhc10027659_10q_htm.xml XML 866990
Mailing Address 37000 GRAND RIVER AVE. SUITE 120 FARMINGTON HILLS MI 48335
Business Address 37000 GRAND RIVER AVE. SUITE 120 FARMINGTON HILLS MI 48335 248-681-9815
Ocuphire Pharma, Inc. (Filer) CIK: 0001228627 (see all company filings)

EIN.: 113516358 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-34079 | Film No.: 211168391
SIC: 2834 Pharmaceutical Preparations